APA (7th ed.) Citation

FH, Z., T, W., YM, H., LH, W., MQ, L., WJ, H., . . . NS, X. (2022). Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: End-of-study analysis of a phase 3, double-blind, randomised, controlled trial. The Lancet. Infectious diseases, 22(12), 1756. https://doi.org/10.1016/S1473-3099(22)00435-2

Chicago Style (17th ed.) Citation

FH, Zhao, et al. "Efficacy, Safety, and Immunogenicity of an Escherichia Coli-produced Human Papillomavirus (16 and 18) L1 Virus-like-particle Vaccine: End-of-study Analysis of a Phase 3, Double-blind, Randomised, Controlled Trial." The Lancet. Infectious Diseases 22, no. 12 (2022): 1756. https://doi.org/10.1016/S1473-3099(22)00435-2.

MLA (9th ed.) Citation

FH, Zhao, et al. "Efficacy, Safety, and Immunogenicity of an Escherichia Coli-produced Human Papillomavirus (16 and 18) L1 Virus-like-particle Vaccine: End-of-study Analysis of a Phase 3, Double-blind, Randomised, Controlled Trial." The Lancet. Infectious Diseases, vol. 22, no. 12, 2022, p. 1756, https://doi.org/10.1016/S1473-3099(22)00435-2.